Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Bladder Cancer, May 2021

Free Subscription


Abstracts

Retrieve all available abstracts of the following 260 articles:
HTML format


 

Single Articles

  1. KOCAN H, Kadihasanoglu M
    Age and sex do not affect first year recurrence in patients with non-muscle invasive bladder cancer.
    Folia Med (Plovdiv). 2021;63:242-246.
    PubMed    
    Abstract available

  2. CHEN S, Jiang L, Zheng X, Shao J, et al
    Clinical use of machine learning-based patho-mics signature for diagnosis and survival prediction of bladder cancer.
    Cancer Sci. 2021 May 1. doi: 10.1111/cas.14927.
    PubMed    
    Abstract available

  3. WANG S, Cai J, Zhang S, Dong M, et al
    Loss of polarity protein Par3, via transcription factor Snail, promotes bladder cancer metastasis.
    Cancer Sci. 2021 May 1. doi: 10.1111/cas.14920.
    PubMed    
    Abstract available

  4. ZHU W, Gao F, Zhou H, Jin K, et al
    Knockdown of MCM8 inhibits development and progression of bladder cancer in vitro and in vivo.
    Cancer Cell Int. 2021;21:242.
    PubMed    
    Abstract available

  5. ZHANG SF, Pang S, Wang FP, Li XY, et al
    Long noncoding RNA OIP5-AS1 exhibits oncogenic activity in bladder cancer through miR-217 and MTDH.
    Eur Rev Med Pharmacol Sci. 2021;25:3211-3220.
    PubMed    
    Abstract available

  6. GUNDOGAN C, Tatar G, Erkan E, Cakir MS, et al
    The impact of IV contrast enhanced (18)F-FDG PET/CT on the staging of bladder cancer.
    Hell J Nucl Med. 2021;24:75-82.
    PubMed    
    Abstract available

  7. SYMON N, Mattout J, Lewin R, Hammer L, et al
    Is Ultra Hypofractionated Radiation Therapy a Safe and Effective Treatment for Invasive Bladder Cancer in the Elderly?: A Retrospective Single Institution Review.
    Am J Clin Oncol. 2021 Apr 29. pii: 00000421-900000000-98571.
    PubMed    
    Abstract available

  8. ZHOU C, Li AH, Liu S, Sun H, et al
    Identification of an 11-Autophagy-Related-Gene Signature as Promising Prognostic Biomarker for Bladder Cancer Patients.
    Biology (Basel). 2021;10.
    PubMed    
    Abstract available

  9. ROSE M, Noetzel E, Kistermann J, Eschenbruch J, et al
    The ECM Modulator ITIH5 Affects Cell Adhesion, Motility and Chemotherapeutic Response of Basal/Squamous-Like (BASQ) Bladder Cancer Cells.
    Cells. 2021;10.
    PubMed    
    Abstract available

  10. TING HK, Chen CL, Meng E, Cherng JH, et al
    Inflammatory Regulation by TNF-alpha-Activated Adipose-Derived Stem Cells in the Human Bladder Cancer Microenvironment.
    Int J Mol Sci. 2021;22.
    PubMed    
    Abstract available

  11. LIN JT, Tsai KW
    Circulating miRNAs Act as Diagnostic Biomarkers for Bladder Cancer in Urine.
    Int J Mol Sci. 2021;22.
    PubMed    
    Abstract available

  12. KLEIN FG, Granier C, Zhao Y, Pan Q, et al
    Combination of Talazoparib and Palbociclib as a Potent Treatment Strategy in Bladder Cancer.
    J Pers Med. 2021;11.
    PubMed    
    Abstract available

  13. WIGNER P, Grebowski R, Bijak M, Saluk-Bijak J, et al
    The Interplay between Oxidative Stress, Inflammation and Angiogenesis in Bladder Cancer Development.
    Int J Mol Sci. 2021;22.
    PubMed    
    Abstract available

  14. MALKIEWICZ B, Kielb P, Gurwin A, Knecht K, et al
    The Usefulness of Lymphadenectomy in Bladder Cancer-Current Status.
    Medicina (Kaunas). 2021;57.
    PubMed    
    Abstract available

  15. WU YS, Ho JY, Yu CP, Cho CJ, et al
    Ellagic Acid Resensitizes Gemcitabine-Resistant Bladder Cancer Cells by Inhibiting Epithelial-Mesenchymal Transition and Gemcitabine Transporters.
    Cancers (Basel). 2021;13.
    PubMed    
    Abstract available

  16. ZHANG X, Taoka R, Liu D, Matsuoka Y, et al
    Knockdown of RRM1 with Adenoviral shRNA Vectors to Inhibit Tumor Cell Viability and Increase Chemotherapeutic Sensitivity to Gemcitabine in Bladder Cancer Cells.
    Int J Mol Sci. 2021;22.
    PubMed    
    Abstract available

  17. LUCZYKOWSKI K, Warmuzinska N, Operacz S, Stryjak I, et al
    Metabolic Evaluation of Urine from Patients Diagnosed with High Grade (HG) Bladder Cancer by SPME-LC-MS Method.
    Molecules. 2021;26.
    PubMed    
    Abstract available

  18. MAMOUNI K, Kim J, Lokeshwar BL, Kallifatidis G, et al
    ARRB1 Regulates Metabolic Reprogramming to Promote Glycolysis in Stem Cell-Like Bladder Cancer Cells.
    Cancers (Basel). 2021;13.
    PubMed    
    Abstract available

  19. MARTINEZ-ROJO E, Berumen LC, Garcia-Alcocer G, Escobar-Cabrera J, et al
    The Role of Androgens and Androgen Receptor in Human Bladder Cancer.
    Biomolecules. 2021;11.
    PubMed    
    Abstract available

  20. HERRMANN J, Schmidt H, Nitschke K, Weis CA, et al
    RNA Expression of DNA Damage Response Genes in Muscle-Invasive Bladder Cancer: Influence on Outcome and Response to Adjuvant Cisplatin-Based Chemotherapy.
    Int J Mol Sci. 2021;22.
    PubMed    
    Abstract available

  21. FORSTER S, Givehchi M, Nitschke K, Mayr T, et al
    Neuropilin-2 and Its Transcript Variants Correlate with Clinical Outcome in Bladder Cancer.
    Genes (Basel). 2021;12.
    PubMed    
    Abstract available

  22. TULCHINER G, Staudacher N, Fritz J, Radmayr C, et al
    The "COVID-19 Pandemic Gap" and Its Influence on Oncologic Outcomes of Bladder Cancer.
    Cancers (Basel). 2021;13.
    PubMed    
    Abstract available

  23. CHARPENTIER M, Gutierrez C, Guillaudeux T, Verhoest G, et al
    Noninvasive Urine-Based Tests to Diagnose or Detect Recurrence of Bladder Cancer.
    Cancers (Basel). 2021;13.
    PubMed    
    Abstract available

  24. GAVRIEL CG, Dimitriou N, Brieu N, Nearchou IP, et al
    Assessment of Immunological Features in Muscle-Invasive Bladder Cancer Prognosis Using Ensemble Learning.
    Cancers (Basel). 2021;13.
    PubMed    
    Abstract available

  25. JAIN P, Kathuria H, Momin M
    Clinical therapies and nano drug delivery systems for urinary bladder cancer.
    Pharmacol Ther. 2021 Apr 26:107871. doi: 10.1016/j.pharmthera.2021.107871.
    PubMed    
    Abstract available

  26. TAMABUCHI E, Fujimura T, Lyu C, Aiba S, et al
    Phosphor-signal transducers and activator of transcription (pSTAT)1 signaling in mucosal lichen planus developing from metastatic bladder cancer treated with pembrolizumab.
    Dermatol Ther. 2021 Apr 28:e14961. doi: 10.1111/dth.14961.
    PubMed    


  27. ABDELGHANI KB, Nacef L, Miladi S, Sellami M, et al
    Reactive Arthritis following Bacillus Calmette-Guerin Therapy for Bladder Cancer: a Systematic Literature Review.
    Curr Rheumatol Rep. 2021;23:39.
    PubMed    
    Abstract available

  28. YAVAS G, Yavas C, Arslan G, Onal C, et al
    Comment on Hunt et al, "Feasibility of magnetic resonance guided radiotherapy for the treatment of bladder cancer".
    Clin Transl Radiat Oncol. 2021;28:88-89.
    PubMed    
    Abstract available

  29. KITAGAWA K, Shigemura K, Ishii A, Nakashima T, et al
    Nanaomycin K inhibited epithelial mesenchymal transition and tumor growth in bladder cancer cells in vitro and in vivo.
    Sci Rep. 2021;11:9217.
    PubMed    
    Abstract available

  30. HARADA J, Miyata Y, Araki K, Matsuda T, et al
    Pathological Significance and Prognostic Roles of Thrombospondin-3, 4 and 5 in Bladder Cancer.
    In Vivo. 2021;35:1693-1701.
    PubMed    
    Abstract available

  31. KELLONIEMI E, Jarvinen R, Hellstrom P, Rintala E, et al
    Repeated 5-aminolevulinic Acid Instillations During Follow-up in Non-muscle-invasive Bladder Cancer: A Randomized Study.
    In Vivo. 2021;35:1561-1568.
    PubMed    
    Abstract available

  32. BOTHIG R, Tiburtius C, Schops W, Zellner M, et al
    Urinary bladder cancer as a late sequela of traumatic spinal cord injury.
    Mil Med Res. 2021;8:29.
    PubMed    
    Abstract available

  33. DE JONG JJ, Stoop H, Boormans JL, van Leenders GJLH, et al
    PD-L1 expression in urothelial bladder cancer varies more among specimen types than between companion assays.
    Virchows Arch. 2021 Apr 28. pii: 10.1007/s00428-021-03094.
    PubMed    
    Abstract available

  34. LI S, Liang P, Wang Y, Feng C, et al
    Combining volumetric apparent diffusion coefficient histogram analysis with vesical imaging reporting and data system to predict the muscle invasion of bladder cancer.
    Abdom Radiol (NY). 2021 Apr 28. pii: 10.1007/s00261-021-03091.
    PubMed    
    Abstract available

  35. XU T, Rao T, Yu WM, Ning JZ, et al
    Upregulation of NFKBIZ affects bladder cancer progression via the PTEN/PI3K/Akt signaling pathway.
    Int J Mol Med. 2021;47.
    PubMed    
    Abstract available

  36. FABIANO E, Durdux C, Dufour B, Mejean A, et al
    Long-term outcomes after bladder-preserving tri-modality therapy for patients with muscle-invasive bladder cancer.
    Acta Oncol. 2021 Apr 27:1-9. doi: 10.1080/0284186X.2021.1915498.
    PubMed    
    Abstract available

  37. YANG Y, Jiang D, Zhou Z, Xiong H, et al
    CDK7 blockade suppresses super-enhancer-associated oncogenes in bladder cancer.
    Cell Oncol (Dordr). 2021 Apr 27. pii: 10.1007/s13402-021-00608.
    PubMed    
    Abstract available

  38. MOHD ARIFFIN K, Abd Ghani F, Hussin H, Md Said S, et al
    Hedgehog signalling molecule, SMO is a poor prognostic marker in bladder cancer.
    Malays J Pathol. 2021;43:49-54.
    PubMed    
    Abstract available

  39. RUAN W, Chen X, Huang M, Wang H, et al
    A urine-based DNA methylation assay to facilitate early detection and risk stratification of bladder cancer.
    Clin Epigenetics. 2021;13:91.
    PubMed    
    Abstract available

  40. XIONG Y, Zu X, Wang L, Li Y, et al
    The VIM-AS1/miR-655/ZEB1 axis modulates bladder cancer cell metastasis by regulating epithelial-mesenchymal transition.
    Cancer Cell Int. 2021;21:233.
    PubMed    
    Abstract available

  41. YANG Y, Zhang H, Liu Z, Zhao F, et al
    EPDR1 is related to stages and metastasize in bladder cancer and can be used as a prognostic biomarker.
    BMC Urol. 2021;21:71.
    PubMed    
    Abstract available

  42. OWARI T, Iwamoto T, Anai S, Miyake M, et al
    The Sustaining of fluorescence in photodynamic diagnosis after the administration of 5-aminolevulinic acid in carcinogen-induced bladder cancer orthotopic rat model and urothelial cancer cell lines.
    Photodiagnosis Photodyn Ther. 2021 Apr 23:102309.
    PubMed    
    Abstract available

  43. ARSLAN O, Soylu NK, Akillilar PT, Tazebay UH, et al
    Coiled-coil domain-containing protein-124 (Ccdc124) is a novel RNA binding factor up-regulated in endometrial, ovarian, and urinary bladder cancers.
    Cancer Biomark. 2021 Mar 26. pii: CBM200802. doi: 10.3233/CBM-200802.
    PubMed    
    Abstract available

  44. SINGH S, Goel S, Iqbal A
    Anatomical segment 4b/5 resection for gall bladder cancer using intraoperative ultrasound.
    J Visc Surg. 2021 Apr 22. pii: S1878-7886(21)00060.
    PubMed    


  45. SUN R, Zhang J, Chen L, Zhang N, et al
    Punica granatum Extract Inhibits Bladder Cancer Cell Viability, Invasion and Migration through Down-Regulation of HOXD10 Signalling Pathway.
    Dokl Biochem Biophys. 2021;497:130-136.
    PubMed    
    Abstract available

  46. KUTWIN P, Borkowska EM, Bogucka P, Jablonowski Z, et al
    Expression profile of microRNAs (106b-3p, 130b-3, 145-3p, 199a-5p) in urine and serum samples from patients with the diagnosis of bladder cancer.
    Pol Merkur Lekarski. 2021;49:103-107.
    PubMed    
    Abstract available

  47. LOEFFLER CML, Ortiz Bruechle N, Jung M, Seillier L, et al
    Artificial Intelligence-based Detection of FGFR3 Mutational Status Directly from Routine Histology in Bladder Cancer: A Possible Preselection for Molecular Testing?
    Eur Urol Focus. 2021 Apr 21. pii: S2405-4569(21)00113.
    PubMed    
    Abstract available

  48. MAO M, Yang L, Hu J, Liu B, et al
    OCT3/4 enhances tumor immune response by upregulating the TET1-dependent NRF2/MDM2 axis in bladder cancer.
    Genomics. 2021 Apr 21. pii: S0888-7543(21)00166.
    PubMed    
    Abstract available



  49. Aktuelle Urol. 2021;52:118-120.
    PubMed    




  50. Aktuelle Urol. 2021;52:112-114.
    PubMed    


  51. WEZEL F, Lustig J, Azoitei A, Liu J, et al
    Grainyhead-Like 3 Influences Migration and Invasion of Urothelial Carcinoma Cells.
    Int J Mol Sci. 2021;22.
    PubMed    
    Abstract available

  52. SCHOLTES MP, Alberts AR, Ifle IG, Verhagen PCMS, et al
    Biomarker-Oriented Therapy in Bladder and Renal Cancer.
    Int J Mol Sci. 2021;22.
    PubMed    
    Abstract available

  53. ZHANG J, Deng X
    Effects of miR-599 targeting YAP1 on proliferation, invasion and apoptosis of bladder urothelial carcinoma cells.
    Exp Mol Pathol. 2021;118:104599.
    PubMed    
    Abstract available

  54. HUANG XZ, Zhou AY, Liu MW, Zhang Y, et al
    Shear Wave Elasticity Differentiation Between Low- and High-Grade Bladder Urothelial Carcinoma and Correlation With Collagen Fiber Content.
    J Ultrasound Med. 2021;40:113-122.
    PubMed    
    Abstract available

  55. STAKHOVSKYI O, Tymoshenko A, Voilenko capital O, Cyrillic, Kononenko O, et al
    ILEOSIGMOID POUCH AS A URINARY DIVERSION APPROACH FOLLOWING RADICAL CYSTECTOMY IN PATIENTS WITH MUSCLE-INVASIVE BLADDER CANCER.
    Georgian Med News. 2021;:36-42.
    PubMed    
    Abstract available

  56. LASHAY A, Taleghani S, Masoumi N
    Comparison of Single Monthly Instillations of Intra-Vesical Bacillus Calmette-Guerin Maintenance Therapy with Southwest Oncology Group Regimen in Non-Muscle Invasive Bladder Cancer Patients-A Retrospective Analysis In a Single Institute.
    Urol J. 2021 May 8. pii: 6491. doi: 10.22037/uj.v18i.6491.
    PubMed    
    Abstract available

  57. TUMEDEI MM, Ravaioli S, Matteucci F, Celli M, et al
    Spotlight on PSMA as a new theranostic biomarker for bladder cancer.
    Sci Rep. 2021;11:9777.
    PubMed    
    Abstract available

  58. MAAS M, Rausch S, Guttenberg T, Seiler R, et al
    Receptor Activator of NF Kappa B (RANK) Expression Indicates Favorable Prognosis in Patients with Muscle-invasive Bladder Cancer.
    Eur Urol Focus. 2021 May 4. pii: S2405-4569(21)00121.
    PubMed    
    Abstract available

  59. WU Q, Zhou X, Li P, Ding M, et al
    ROC1 promotes the malignant progression of bladder cancer by regulating p-IkappaBalpha/NF-kappaB signaling.
    J Exp Clin Cancer Res. 2021;40:158.
    PubMed    
    Abstract available

  60. SUN X, Zhou Z, Zhang Y, Wang J, et al
    Identification and validation of a hypoxia-related prognostic and immune microenvironment signature in bladder cancer.
    Cancer Cell Int. 2021;21:251.
    PubMed    
    Abstract available

  61. ZHANG J, Zhang C, Cao P, Zheng X, et al
    A zinc finger protein gene signature enables bladder cancer treatment stratification.
    Aging (Albany NY). 2021;13.
    PubMed    
    Abstract available

  62. DAI ZT, Xiang Y, Wang Y, Bao LY, et al
    Prognostic value of members of NFAT family for pan-cancer and a prediction model based on NFAT2 in bladder cancer.
    Aging (Albany NY). 2021;13.
    PubMed    
    Abstract available

  63. CAO R, Ma B, Wang G, Xiong Y, et al
    Identification of autophagy-related genes signature predicts chemotherapeutic and immunotherapeutic efficiency in bladder cancer (BLCA).
    J Cell Mol Med. 2021 May 7. doi: 10.1111/jcmm.16552.
    PubMed    
    Abstract available

  64. JIN F, Shahid M, Kim J
    Research Progress of Urine Biomarkers in the Diagnosis, Treatment, and Prognosis of Bladder Cancer.
    Adv Exp Med Biol. 2021;1306:61-80.
    PubMed    
    Abstract available

  65. LI S, Lu S, Liu X, Chen X, et al
    Association Between the Pretreatment Albumin-to-Alkaline Phosphatase Ratio and Clinical Outcomes in Patients With Bladder Cancer Treated With Radical Cystectomy: A Retrospective Cohort Study.
    Front Oncol. 2021;11:664392.
    PubMed    
    Abstract available

  66. SONPAVDE GP
    Management of Bladder Cancer: The First Inning of a New Era of Rapid Advances.
    Hematol Oncol Clin North Am. 2021;35:xiii-xx.
    PubMed    


  67. BANGS R, Quale DZ
    Future Directions in Bladder Cancer Treatment and Research-The Patient Advocates' Perspective.
    Hematol Oncol Clin North Am. 2021;35:655-664.
    PubMed    
    Abstract available

  68. GUERCIO BJ, Iyer G, Rosenberg JE
    Developing Precision Medicine for Bladder Cancer.
    Hematol Oncol Clin North Am. 2021;35:633-653.
    PubMed    
    Abstract available

  69. ZHU S, Zhu Z, Ma AH, Sonpavde GP, et al
    Preclinical Models for Bladder Cancer Research.
    Hematol Oncol Clin North Am. 2021;35:613-632.
    PubMed    
    Abstract available

  70. PFAIL JL, Small AC, Cumarasamy S, Galsky MD, et al
    Real World Outcomes of Patients with Bladder Cancer: Effectiveness Versus Efficacy of Modern Treatment Paradigms.
    Hematol Oncol Clin North Am. 2021;35:597-612.
    PubMed    
    Abstract available

  71. THIBAULT C, Loriot Y
    Emerging Targeted Therapy for Bladder Cancer.
    Hematol Oncol Clin North Am. 2021;35:585-596.
    PubMed    
    Abstract available

  72. KONIECZKOWSKI DJ, Efstathiou JA, Mouw KW
    Contemporary and Emerging Approaches to Bladder-Preserving Trimodality Therapy for Muscle-Invasive Bladder Cancer.
    Hematol Oncol Clin North Am. 2021;35:567-584.
    PubMed    
    Abstract available

  73. AHMADI H, Duddalwar V, Daneshmand S
    Diagnosis and Staging of Bladder Cancer.
    Hematol Oncol Clin North Am. 2021;35:531-541.
    PubMed    
    Abstract available

  74. BREE KK, Brooks NA, Kamat AM
    Current Therapy and Emerging Intravesical Agents to Treat Non-Muscle Invasive Bladder Cancer.
    Hematol Oncol Clin North Am. 2021;35:513-529.
    PubMed    
    Abstract available

  75. MA J, Black PC
    Current Perioperative Therapy for Muscle Invasive Bladder Cancer.
    Hematol Oncol Clin North Am. 2021;35:495-511.
    PubMed    
    Abstract available

  76. MCCONKEY DJ
    Molecular Biology of Bladder Cancer: Potential Implications for Therapy.
    Hematol Oncol Clin North Am. 2021;35:457-468.
    PubMed    
    Abstract available

  77. MOSSANEN M
    The Epidemiology of Bladder Cancer.
    Hematol Oncol Clin North Am. 2021;35:445-455.
    PubMed    
    Abstract available

  78. ALLEN BC, Oto A, Akin O, Alexander LF, et al
    ACR Appropriateness Criteria(R) Post-Treatment Surveillance of Bladder Cancer: 2021 Update.
    J Am Coll Radiol. 2021;18.
    PubMed    
    Abstract available

  79. SUN H, Ou T, Hu J, Yang Z, et al
    Nitazoxanide impairs mitophagy flux through ROS-mediated mitophagy initiation and lysosomal dysfunction in bladder cancer.
    Biochem Pharmacol. 2021 May 3:114588. doi: 10.1016/j.bcp.2021.114588.
    PubMed    
    Abstract available

  80. KABHA A, Bukchin-Tihomirov A, Shlomi I, Ammar AA, et al
    Biodegradable Controlled-Release Device for Localized Chemotherapeutic Treatment of Bladder Cancer.
    ACS Biomater Sci Eng. 2021 May 6. doi: 10.1021/acsbiomaterials.1c00339.
    PubMed    
    Abstract available

  81. JEONG H, Park KJ, Lee YJ, Kim HD, et al
    The Prognosis and the Role of Adjuvant Chemotherapy for Node-Positive Bladder Cancer Treated with Neoadjuvant Chemotherapy Followed by Surgery.
    Cancer Res Treat. 2021 May 6. pii: crt.2021.365. doi: 10.4143/crt.2021.
    PubMed    
    Abstract available

  82. WU H, Zhang ZY, Zhang Z, Xiao XY, et al
    Prediction of bladder cancer outcome by identifying and validating a mutation-derived genomic instability-associated long noncoding RNA (lncRNA) signature.
    Bioengineered. 2021;12:1725-1738.
    PubMed    
    Abstract available

  83. FUKUI-KAWAURA S, Kawahara T, Araki Y, Nishimura R, et al
    A higher De Ritis ratio (AST/ALT) is a risk factor for progression in high-risk non-muscle invasive bladder cancer.
    Oncotarget. 2021;12:917-922.
    PubMed    
    Abstract available

  84. KIM MH, Yang GE, Jeong MS, Mun JY, et al
    VNTR polymorphism in the breakpoint region of ABL1 and susceptibility to bladder cancer.
    BMC Med Genomics. 2021;14:121.
    PubMed    
    Abstract available

  85. SONG H, Zeng J, Lele S, LaGrange CA, et al
    APE1 and SSRP1 is overexpressed in muscle invasive bladder cancer and associated with poor survival.
    Heliyon. 2021;7:e06756.
    PubMed    
    Abstract available

  86. WANG X, Qiao G, Jiang N, Morse MA, et al
    Serial assessment of circulating T lymphocyte phenotype and receptor repertoire during treatment of non-muscle invasive bladder cancer with adoptive T cell immunotherapy.
    Am J Cancer Res. 2021;11:1709-1718.
    PubMed    
    Abstract available

  87. MELO MN, Pereira FM, Rocha MA, Ribeiro JG, et al
    Chitosan and chitosan/PEG nanoparticles loaded with indole-3-carbinol: Characterization, computational study and potential effect on human bladder cancer cells.
    Mater Sci Eng C Mater Biol Appl. 2021;124:112089.
    PubMed    
    Abstract available

  88. NAGUMO Y, Kandori S, Tanuma K, Nitta S, et al
    PLD1 promotes tumor invasion by regulation of MMP-13 expression via NF-kappaB signaling in bladder cancer.
    Cancer Lett. 2021;511:15-25.
    PubMed    
    Abstract available

  89. LIU Y, Wang G, Cui T, Lv L, et al
    Adhesion GPR123 is an indicator for recurrence and prognosis in bladder cancer.
    Genes Genomics. 2021 May 4. pii: 10.1007/s13258-021-01108.
    PubMed    
    Abstract available

  90. BOCCHIALINI T, Ziglioli F, Palmieri G, Barbieri A, et al
    Mullerianosis of the urinary bladder may simulate a bladder cancer: a case report.
    Acta Biomed. 2021;92.
    PubMed    
    Abstract available

  91. RAZZAGHDOUST A, Ghajari M, Basiri A, Torbati PM, et al
    Association of immunohistochemical markers of tumor subtype with response to neoadjuvant chemotherapy and survival in patients with muscle-invasive bladder cancer.
    Investig Clin Urol. 2021;62:274-281.
    PubMed    
    Abstract available

  92. PELEGRIN-MATEO FJ, Segui-Moya E, Fernandez-Cruz M, Garcia-Segui A, et al
    [Bladder paraganglioma: Report of two cases and a literature review.]
    Arch Esp Urol. 2021;74:445-449.
    PubMed    
    Abstract available

  93. MARTINEZ RODRIGUEZ R, Portilla Mediavilla L, Alves Oliveira M, Elias X, et al
    [Can a single value of a perypheric inflammatory response marker predict the response to BCG?]
    Arch Esp Urol. 2021;74:404-410.
    PubMed    
    Abstract available

  94. DIZMAN N, Meza L, Pal SK
    Biomarker approach harnessed in trials of personalized medicine for bladder cancer.
    Nat Med. 2021 May 3. pii: 10.1038/s41591-021-01300.
    PubMed    


  95. BHINDI B, Kool R, Kulkarni GS, Siemens DR, et al
    Canadian Urological Association guideline on the management of non-muscle invasive bladder cancer.
    Can Urol Assoc J. 2021 Apr 26. pii: cuaj.7367. doi: 10.5489/cuaj.7367.
    PubMed    


  96. WAN S, Liu X, Hua W, Xi M, et al
    The role of telomerase reverse transcriptase (TERT) promoter mutations in prognosis in bladder cancer.
    Bioengineered. 2021;12:1495-1504.
    PubMed    
    Abstract available

  97. ZHANG LH, Li LQ, Zhan YH, Zhu ZW, et al
    Identification of an IRGP Signature to Predict Prognosis and Immunotherapeutic Efficiency in Bladder Cancer.
    Front Mol Biosci. 2021;8:607090.
    PubMed    
    Abstract available

  98. CHEN X, Chen H, He D, Cheng Y, et al
    Analysis of Tumor Microenvironment Characteristics in Bladder Cancer: Implications for Immune Checkpoint Inhibitor Therapy.
    Front Immunol. 2021;12:672158.
    PubMed    
    Abstract available

  99. SUNG HH, Scherr DS, Slaton J, Liu H, et al
    Phase II multi-center trial of optical coherence tomography as an adjunct to white light cystoscopy for intravesical real time imaging and staging of bladder cancer.
    Urol Oncol. 2021 Apr 29. pii: S1078-1439(21)00136.
    PubMed    
    Abstract available

  100. XIA Y, Chen S, Cui J, Wang Y, et al
    Berberine suppresses bladder cancer cell proliferation by inhibiting JAK1-STAT3 signaling via upregulation of miR-17-5p.
    Biochem Pharmacol. 2021;188:114575.
    PubMed    
    Abstract available

  101. HUANG CP, Wu CC, Shyr CR
    Combination of novel intravesical xenogeneic urothelial cell immunotherapy and chemotherapy enhances anti-tumor efficacy in preclinical murine bladder tumor models.
    Cancer Immunol Immunother. 2021;70:1419-1433.
    PubMed    
    Abstract available

  102. KHADRAOUI W, Tymon-Rosario J, Nagarkatti N, Menderes G, et al
    Robotic Low Anterior Resection and Partial Bladder Resection for Management of Locoregional Endometrial Cancer Recurrence.
    J Minim Invasive Gynecol. 2021;28:176-177.
    PubMed    
    Abstract available

  103. WANG JZ, Zhu W, Han J, Yang X, et al
    The role of the HIF-1alpha/ALYREF/PKM2 axis in glycolysis and tumorigenesis of bladder cancer.
    Cancer Commun (Lond). 2021 May 15. doi: 10.1002/cac2.12158.
    PubMed    
    Abstract available

  104. CHENARD S, Robert Siemens D, Koti M
    The CXCR3alt-CXCL11 axis in bladder cancer: potential for prediction of neoadjuvant chemotherapy response.
    Cell Mol Immunol. 2021 May 14. pii: 10.1038/s41423-021-00692.
    PubMed    


  105. SARGOS P, Baumann BC, Faye MD, Fonteyne V, et al
    A Tailored Radiation Therapy Strategy for Older Patients With Localized Bladder Cancer Not Eligible for Curative Treatment.
    Int J Radiat Oncol Biol Phys. 2021;110:425-428.
    PubMed    


  106. HUANG H, Du J, Jin B, Pang L, et al
    Combination of Urine Exosomal mRNAs and lncRNAs as Novel Diagnostic Biomarkers for Bladder Cancer.
    Front Oncol. 2021;11:667212.
    PubMed    
    Abstract available

  107. ISONO M, Okubo K, Asano T, Sato A, et al
    Inhibition of checkpoint kinase 1 potentiates anticancer activity of gemcitabine in bladder cancer cells.
    Sci Rep. 2021;11:10181.
    PubMed    
    Abstract available

  108. SHINDE-JADHAV S, Mansure JJ, Rayes RF, Marcq G, et al
    Role of neutrophil extracellular traps in radiation resistance of invasive bladder cancer.
    Nat Commun. 2021;12:2776.
    PubMed    
    Abstract available

  109. TANG C, Yu M, Ma J, Zhu Y, et al
    Metabolic classification of bladder cancer based on multi-omics integrated analysis to predict patient prognosis and treatment response.
    J Transl Med. 2021;19:205.
    PubMed    
    Abstract available

  110. ZHENG Z, Zheng X, Zhu Y, Yao Z, et al
    IL-6 Promotes the Proliferation and Immunosuppressive Function of Myeloid-Derived Suppressor Cells via the MAPK Signaling Pathway in Bladder Cancer.
    Biomed Res Int. 2021;2021:5535578.
    PubMed    
    Abstract available

  111. ZHENG Z, Xu F, Gu Z, Yan Y, et al
    Integrating multiparametric MRI radiomics features and the Vesical Imaging-Reporting and Data System (VI-RADS) for bladder cancer grading.
    Abdom Radiol (NY). 2021 May 12. pii: 10.1007/s00261-021-03108.
    PubMed    
    Abstract available

  112. BITINA-BARLOTE E, Plonis J, Cauce V, Vjaters E, et al
    Bladder cancer trends in Latvia during 1990-2017: incidence, mortality, and survival rates.
    Cent European J Urol. 2021;74:14-23.
    PubMed    
    Abstract available

  113. GREEN EA, Li R, Albiges L, Choueiri TK, et al
    Clinical Utility of Cell-free and Circulating Tumor DNA in Kidney and Bladder Cancer: A Critical Review of Current Literature.
    Eur Urol Oncol. 2021 May 8. pii: S2588-9311(21)00079.
    PubMed    
    Abstract available

  114. LU Q, Cai P, Yu Y, Liu Z, et al
    Sema4D correlates with tumour immune infiltration and is a prognostic biomarker in bladder cancer, renal clear cell carcinoma, melanoma and thymoma.
    Autoimmunity. 2021 May 11:1-9. doi: 10.1080/08916934.2021.1925885.
    PubMed    
    Abstract available

  115. GENG H, Zhou Q, Guo W, Lu L, et al
    Exosomes in bladder cancer: novel biomarkers and targets.
    J Zhejiang Univ Sci B. 2021;22:341-347.
    PubMed    
    Abstract available

  116. MILLERICK-MAY ML, Wang L, Rice C, Rosenman KD, et al
    Ongoing risk of bladder cancer among former workers at the last benzidine manufacturing facility in the USA.
    Occup Environ Med. 2021 May 10. pii: oemed-2020-106431.
    PubMed    
    Abstract available

  117. DEUKER M, Krimphove MJ, Stolzenbach LF, Colla Ruvolo C, et al
    Radical Cystectomy vs. Multimodality Treatment in T2N0M0 Bladder Cancer: A Population-based, Age-matched Analysis.
    Clin Genitourin Cancer. 2021 Apr 8. pii: S1558-7673(21)00073.
    PubMed    
    Abstract available

  118. GARG T, Johns A, Young AJ, Nielsen ME, et al
    Geriatric conditions and treatment burden following diagnosis of non-muscle- invasive bladder Cancer in older adults: A population-based analysis.
    J Geriatr Oncol. 2021 May 7. pii: S1879-4068(21)00104.
    PubMed    
    Abstract available

  119. BAUMANN BC, Zaghloul MS, Sargos P, Murthy V, et al
    Adjuvant and Neoadjuvant Radiation Therapy for Locally Advanced Bladder Cancer.
    Clin Oncol (R Coll Radiol). 2021;33:391-399.
    PubMed    
    Abstract available

  120. KONG V, Hansen VN, Hafeez S
    Image-guided Adaptive Radiotherapy for Bladder Cancer.
    Clin Oncol (R Coll Radiol). 2021;33:350-368.
    PubMed    
    Abstract available

  121. URABE F, Kimura T, Ito K, Yamamoto Y, et al
    Urinary extracellular vesicles: a rising star in bladder cancer management.
    Transl Androl Urol. 2021;10:1878-1889.
    PubMed    
    Abstract available

  122. PING Q, Shi Y, Yang M, Li H, et al
    LncRNA DANCR regulates lymphatic metastasis of bladder cancer via the miR-335/VEGF-C axis.
    Transl Androl Urol. 2021;10:1743-1753.
    PubMed    
    Abstract available

  123. POPOV H, Kobakova I, Stoyanov GS, Softova E, et al
    Quantitative Analysis of Tumor-Associated Mast Cells in Recurrent and Non-recurrent Urothelial Bladder Cancer in Stage pTa and pT1.
    Cureus. 2021;13:e14311.
    PubMed    
    Abstract available

  124. MIR MC, Campi R, Loriot Y, Puente J, et al
    Adjuvant Systemic Therapy for High-risk Muscle-invasive Bladder Cancer After Radical Cystectomy: Current Options and Future Opportunities.
    Eur Urol Oncol. 2021 May 6. pii: S2588-9311(21)00078.
    PubMed    
    Abstract available

  125. DE NUNZIO C, Franco A, Simone G, Tuderti G, et al
    Validation of the COBRA nomogram for the prediction of cancer specific survival in patients treated with radical cystectomy for bladder cancer: An international wide cohort study.
    Eur J Surg Oncol. 2021 Apr 30. pii: S0748-7983(21)00466.
    PubMed    
    Abstract available

  126. ALANEE S, Sana S, El-Zawahry A, Peabody J, et al
    Phase I trial of intravesical Bacillus Calmette-Guerin combined with intravenous pembrolizumab in recurrent or persistent high-grade non-muscle-invasive bladder cancer after previous Bacillus Calmette-Guerin treatment.
    World J Urol. 2021 May 8. pii: 10.1007/s00345-021-03716.
    PubMed    
    Abstract available

  127. GVOZDEV MY, Arefyeva OA, Dzhuraeva MD
    [linical case: enterocele after radical cystectomy with heterotopic bladder plastic surgery].
    Urologiia. 2021;:90-93.
    PubMed    
    Abstract available

  128. MAESAKA F, Momose H, Nakahama T, Yamada A, et al
    [A Case of Bladder Squamous Cell Carcinoma with Neurogenic Bladder Caused by Myelomeningocele].
    Hinyokika Kiyo. 2021;67:103-107.
    PubMed    
    Abstract available

  129. CITO G, Santi R, Gemma L, Galli IC, et al
    Angiosarcoma of the Urinary Bladder Following Radiotherapy: Report of a Case and Review of the Literature.
    Medicina (Kaunas). 2021;57.
    PubMed    
    Abstract available

  130. VARSHNEY B, Choudhary GR, Yadav T, Nalwa A, et al
    Sarcomatoid urothelial carcinoma of the bladder with osseous metaplasia: bone in urinary bladder.
    BMJ Case Rep. 2021;14.
    PubMed    
    Abstract available

  131. DING Y, Liu N, Chen M, Xu Y, et al
    Overexpressed pseudogene MT1L associated with tumor immune infiltrates and indicates a worse prognosis in BLCA.
    World J Surg Oncol. 2021;19:133.
    PubMed    
    Abstract available

  132. BUTEA-BOCU MC, Muller G, Brock O, Otto U, et al
    [Metabolic acidosis in neobladder patients : Risk factors and treatment options].
    Urologe A. 2021;60:617-623.
    PubMed    
    Abstract available

  133. VAN ALLEN J
    A rare case of urachal adenocarcinoma with bone marrow metastasis.
    BMJ Case Rep. 2021;14.
    PubMed    
    Abstract available

  134. KUMAR S, Thummala Y, Parmar KM, Chandna A, et al
    Bacillus Calmette-Guerin (BCG)-induced balanitis following intravesical immunotherapy for urothelial cancer.
    BMJ Case Rep. 2021;14.
    PubMed    


  135. CHENG R, Liu X, Wang Z, Tang K, et al
    ABT737, a Bcl2 family inhibitor, has a synergistic effect with apoptosis by inducing urothelial carcinoma cell necroptosis.
    Mol Med Rep. 2021;23.
    PubMed    
    Abstract available

  136. CHAUDHARY K, Pareek T, Sharma A, Thirunavukkarasu B, et al
    Lipid-rich variant of urothelial carcinoma: a lethal enigma.
    BMJ Case Rep. 2021;14.
    PubMed    
    Abstract available

  137. SHAO K, Zhou Z, Xun P, Cohen SM, et al
    Bayesian benchmark dose analysis for inorganic arsenic in drinking water associated with bladder and lung cancer using epidemiological data.
    Toxicology. 2021;455:152752.
    PubMed    
    Abstract available

  138. YANG L, Zou X, Zou J, Zhang G, et al
    Functions of circular RNAs in bladder, prostate and renal cell cancer (Review).
    Mol Med Rep. 2021;23.
    PubMed    
    Abstract available

  139. WANG S, Jin S, Li G, Xu M, et al
    Transmucosal Delivery of Self-Assembling Photosensitizer-Nitazoxanide Nanocomplexes with Fluorinated Chitosan for Instillation-Based Photodynamic Therapy of Orthotopic Bladder Tumors.
    ACS Biomater Sci Eng. 2021;7:1485-1495.
    PubMed    
    Abstract available

  140. HOWE AS, Pearce J, Lian F, Ribbons L, et al
    A Case of Ewing Sarcoma of the Bladder Presenting in Early Infancy.
    J Pediatr Hematol Oncol. 2021;43:e478-e480.
    PubMed    
    Abstract available

  141. RAPISARDA S, Bada M, Polara A, Crocetto F, et al
    Conservative management of primary malignant melanoma of the bladder: a case report.
    J Med Case Rep. 2021;15:39.
    PubMed    
    Abstract available

  142. MATZEN M, Offermann A, Tharun L, Perner S, et al
    [Intravesical Gemcitabine instillations following BCG failure and allergy to Mitomycin: A unique case of a patient with an inverted papilloma of the bladder].
    Aktuelle Urol. 2021;52:43-46.
    PubMed    
    Abstract available

  143. REXER H, Retz M, Kramer M

    Aktuelle Urol. 2021;52:28-29.
    PubMed    


  144. DENG M, Wei W, Duan J, Chen R, et al
    ZHX3 promotes the progression of urothelial carcinoma of the bladder via repressing of RGS2 and is a novel substrate of TRIM21.
    Cancer Sci. 2021;112:1758-1771.
    PubMed    
    Abstract available

  145. MIYAKAWA J, Kawai T, Makino K, Akiyama Y, et al
    Impact of age, body mass index, and renal function for severe hypotension caused by oral 5-aminolevulinic acid administration in patients undergoing transurethral resection of bladder tumor.
    Photodiagnosis Photodyn Ther. 2021;33:102179.
    PubMed    
    Abstract available

  146. REYNOLDS BR, McCombie S, Botha E, Hawks C, et al
    Ten-year outcomes of the first 'one-stop haematuria clinic' in an Australian public hospital.
    ANZ J Surg. 2021;91:565-570.
    PubMed    
    Abstract available

  147. LIU H, Mei C, Deng X, Lin W, et al
    Rapid visualizing and pathological grading of bladder tumor tissues by simple nanodiagnostics.
    Biomaterials. 2021;264:120434.
    PubMed    
    Abstract available

  148. RAVI P, Sonpavde GP
    Considerations in prescribing pharmacotherapy for localized and metastatic urothelial carcinoma.
    Expert Opin Pharmacother. 2021;22:1-4.
    PubMed    


  149. UENO Y, Tamada T, Takeuchi M, Sofue K, et al
    Vesicle Imaging and Data Reporting System (VI-RADS): Multi-institutional multi-reader diagnostic accuracy and inter-observer agreement study.
    AJR Am J Roentgenol. 2020 Jul 29. doi: 10.2214/AJR.20.23604.
    PubMed    
    Abstract available

  150. DRESSLER FF, Dogan S, Hennig M, Frank T, et al
    [Current practice patterns of perioperative cystectomy management in Germany: a questionnaire survey].
    Aktuelle Urol. 2021;52:82-87.
    PubMed    
    Abstract available

  151. LARENTZAKIS A, Eleftheriou MM, Zografos CG, Manolis IT, et al
    Cyclops' eye-like large ulcerated umbilical mass: a rare presentation of urachal cancer.
    ANZ J Surg. 2021;91.
    PubMed    


  152. SPENCER K, Kim LH, Daly T, Lau H, et al
    'Ooosh' haematuria syndrome from eroded and kinked vascular graft in the bladder.
    ANZ J Surg. 2021;91.
    PubMed    


  153. YOLDAS M, Turk H, Yoldas TK
    Clinical and pathological factors predictive of bladder cancer recurrence in patients with upper tract primary TCC.
    Niger J Clin Pract. 2021;24:774-777.
    PubMed    
    Abstract available

  154. CARY C, Militello L, DeChant P, Frankel R, et al
    Barriers to single-dose intravesical chemotherapy in non-muscle invasive bladder cancer: what's the problem?
    Urol Pract. 2021;8:291-297.
    PubMed    
    Abstract available

  155. BARRY E, Agalliu I, Maiman R, Shreck E, et al
    OUTCOMES OF INTRAVESICAL BACILLUS CALMETTE-GUERIN IN A MULTIRACIAL COHORT WITH NON-MUSCLE-INVASIVE BLADDER CANCER.
    Urol Pract. 2021;8:100-105.
    PubMed    
    Abstract available

  156. MOKHTAR A, Kong C, Zhang Z, Du Y, et al
    Down-regulation LncRNA-SNHG15 contributes to proliferation and invasion of bladder cancer cells.
    BMC Urol. 2021;21:83.
    PubMed    
    Abstract available

  157. LU XS, Huang ML, Chen LB, Liu SC, et al
    SCARA5 regulated by MEG3/miR-141 axis attenuates proliferation, migration and invasion of bladder cancer.
    Life Sci. 2021 May 17:119619. doi: 10.1016/j.lfs.2021.119619.
    PubMed    
    Abstract available

  158. WU J, Hu X, Wang X
    Comment to: Effectiveness of contrast-enhanced ultrasound for detecting the staging and grading of bladder cancer: a systematic review and meta-analysis.
    Med Ultrason. 2021;23:245-247.
    PubMed    
    Abstract available

  159. BUCHLER J, Gschwend JE, Retz M, Schmid SC, et al
    [Muscle-invasive bladder cancer].
    Urologe A. 2021 May 20. pii: 10.1007/s00120-021-01536.
    PubMed    
    Abstract available

  160. MAR N, Kalebasty AR
    Adjuvant pembrolizumab in genomically selected high-risk patients with muscle-invasive bladder cancer.
    J Oncol Pharm Pract. 2021 May 20:10781552211016526.
    PubMed    
    Abstract available

  161. GOYAL A, O'Leary D, Goyal K, Rubin N, et al
    Screening for second malignancies in mycosis fungoides: Non-Hodgkin lymphoma, Hodgkin lymphoma, lung cancer, bladder cancer, and melanoma.
    J Eur Acad Dermatol Venereol. 2021 May 20. doi: 10.1111/jdv.17384.
    PubMed    
    Abstract available

  162. LI X, Feng J, Sun Y, Li X, et al
    An Exploration of the Tumor Microenvironment Identified a Novel Five-Gene Model for Predicting Outcomes in Bladder Cancer.
    Front Oncol. 2021;11:642527.
    PubMed    
    Abstract available

  163. DUBOIS J, Rueger J, Haubold B, Far RK, et al
    Transcriptome analyses of urine RNA reveal tumor markers for human bladder cancer: validated amplicons for RT-qPCR-based detection.
    Oncotarget. 2021;12:1011-1023.
    PubMed    
    Abstract available

  164. DEL FAVERO G, Zeugswetter M, Kiss E, Marko D, et al
    Endoplasmic Reticulum Adaptation and Autophagic Competence Shape Response to Fluid Shear Stress in T24 Bladder Cancer Cells.
    Front Pharmacol. 2021;12:647350.
    PubMed    
    Abstract available

  165. GARRIS CS, Wong JL, Ravetch JV, Knorr DA, et al
    Dendritic cell targeting with Fc-enhanced CD40 antibody agonists induces durable antitumor immunity in humanized mouse models of bladder cancer.
    Sci Transl Med. 2021;13.
    PubMed    
    Abstract available

  166. CISAROVSKY C, Latifyan S, Perrinjaquet C, Berthold D, et al
    [Immunotherapy for bladder cancer in 2021].
    Rev Med Suisse. 2021;17:974-977.
    PubMed    
    Abstract available

  167. KAYAMA E, Shigeta K, Kikuchi E, Ogihara K, et al
    Guideline adherence for radical cystectomy significantly affects survival outcomes in non-muscle-invasive bladder cancer patients.
    Jpn J Clin Oncol. 2021 May 3. pii: 6261378. doi: 10.1093.
    PubMed    
    Abstract available

  168. GALSKY MD, Hoimes CJ, Necchi A, Shore N, et al
    Perioperative pembrolizumab therapy in muscle-invasive bladder cancer: Phase III KEYNOTE-866 and KEYNOTE-905/EV-303.
    Future Oncol. 2021 May 19. doi: 10.2217/fon-2021-0273.
    PubMed    
    Abstract available

  169. RICHTERS A, Meijer RP, Mehra N, Boormans JL, et al
    Prospective bladder cancer infrastructure for experimental and observational research on bladder cancer: study protocol for the 'trials within cohorts' study ProBCI.
    BMJ Open. 2021;11:e047256.
    PubMed    
    Abstract available

  170. LIU L, Cui J, Zhao Y, Liu X, et al
    KDM6A-ARHGDIB axis blocks metastasis of bladder cancer by inhibiting Rac1.
    Mol Cancer. 2021;20:77.
    PubMed    
    Abstract available

  171. WANG P, Xiao S, Fu W, Song Y, et al
    Robot-assisted radical cystectomy with intracorporeal Mainz rectosigmoid pouch for muscle-invasive bladder cancer.
    Int J Med Robot. 2021 May 18:e2284. doi: 10.1002/rcs.2284.
    PubMed    
    Abstract available

  172. HAN CT, Bao QY, Cheng SJ, Liu M, et al
    Circular RNA hsa_circ_0017247 acts as an oncogene in bladder cancer by inducing Wnt/beta-catenin signaling pathway.
    Eur Rev Med Pharmacol Sci. 2021;25:3395.
    PubMed    
    Abstract available

  173. MA W, Ou T, Cui X, Wu K, et al
    HSP47 contributes to angiogenesis by induction of CCL2 in bladder cancer.
    Cell Signal. 2021 May 14:110044. doi: 10.1016/j.cellsig.2021.110044.
    PubMed    
    Abstract available


  174. Erratum: Molecular Biomarkers of Response to PD-1/ PD-L1 Immune Checkpoint Blockade in Advanced Bladder Cancer.
    Bladder Cancer. 2021;7:109.
    PubMed    
    Abstract available

  175. BLINDHEIM AJ, Fossa SD, Babigumira R, Andreassen BK, et al
    The use of reTURB in T1 bladder cancer: a Norwegian population-based study.
    Scand J Urol. 2021 May 17:1-7. doi: 10.1080/21681805.2021.1917652.
    PubMed    
    Abstract available

  176. WANG X, Tu N, Sun F, Wen Z, et al
    Detecting Muscle Invasion of Bladder Cancer Using a Proposed Magnetic Resonance Imaging Strategy.
    J Magn Reson Imaging. 2021 May 17. doi: 10.1002/jmri.27676.
    PubMed    
    Abstract available

  177. YIN Z, Li J, Kang L, Liu X, et al
    Epigallocatechin-3-gallate induces autophagy-related apoptosis associated with LC3B II and Beclin expression of bladder cancer cells.
    J Food Biochem. 2021 May 16:e13758. doi: 10.1111/jfbc.13758.
    PubMed    
    Abstract available

  178. AALAMI AH, Abdeahad H, Mesgari M, Sathyapalan T, et al
    Urinary Angiogenin as a Marker for Bladder Cancer: A Meta-Analysis.
    Biomed Res Int. 2021;2021:5557309.
    PubMed    
    Abstract available

  179. ZHANG J, Dai D, Tian J, Li L, et al
    Circulating Tumor DNA Analyses Predict Disease Recurrence in Non-Muscle-Invasive Bladder Cancer.
    Front Oncol. 2021;11:657483.
    PubMed    
    Abstract available

  180. XIA Y, Chen R, Lu G, Li C, et al
    Natural Phytochemicals in Bladder Cancer Prevention and Therapy.
    Front Oncol. 2021;11:652033.
    PubMed    
    Abstract available

  181. ROSSER CJ, Tikhonenkov S, Nix JW, Chan OTM, et al
    Safety, Tolerability, and Long-Term Clinical Outcomes of an IL-15 analogue (N-803) Admixed with Bacillus Calmette-Guerin (BCG) for the Treatment of Bladder Cancer.
    Oncoimmunology. 2021;10:1912885.
    PubMed    
    Abstract available

  182. CHATURVEDI A, Kumar V, Gupta S
    Molecular Oncology of Gall Bladder Cancer.
    Indian J Surg Oncol. 2021;12.
    PubMed    
    Abstract available

  183. JUE JS, Alameddine M, Gonzalez J, Ciancio G, et al
    Risk factors, management, and survival of bladder cancer after kidney transplantation.
    Actas Urol Esp (Engl Ed). 2021 May 11. pii: S0210-4806(21)00063.
    PubMed    
    Abstract available

  184. RAVANINI JN, Assato AK, Wakamatsu A, Alves VAF, et al
    Combined use of immunohistochemical markers of basal and luminal subtypes in urothelial carcinoma of the bladder: Association with clinicopathological features and outcomes.
    Clinics (Sao Paulo). 2021;76:e2587.
    PubMed    
    Abstract available

  185. MAIBOM SL, Joensen UN, Poulsen AM, Kehlet H, et al
    Short-term morbidity and mortality following radical cystectomy: a systematic review.
    BMJ Open. 2021;11:e043266.
    PubMed    
    Abstract available

  186. KALEMCI S, Kizilay F, Simsir A
    A new technique in the treatment of ureteroenteric anastomosis stricture: Repair of ureteroenteric anastomosis stricture with low lombotomy incision (retroperitoneal approach).
    Int J Clin Pract. 2021;75:e14155.
    PubMed    
    Abstract available

  187. TRIPATHI K, Goel A, Singhai A, Garg M, et al
    Promoter hypomethylation as potential confounder of Ras gene overexpression and their clinical significance in subsets of urothelial carcinoma of bladder.
    Mol Biol Rep. 2021;48:2183-2199.
    PubMed    
    Abstract available

  188. SLEIWAH A, Mughal M, Thurairaja R, Khan M, et al
    Reconstructive perineal surgery in the era of robotic surgical systems: Embracing the new technology.
    J Plast Reconstr Aesthet Surg. 2021;74:1101-1160.
    PubMed    


  189. ALDHAAM NA, Hussein A, Elsayed AS, Jing Z, et al
    Detailed Analysis of Urinary Tract Infections after Robot-Assisted Radical Cystectomy.
    J Endourol. 2020 Jul 14. doi: 10.1089/end.2020.0316.
    PubMed    
    Abstract available

  190. TAN SH, Ding HJ, Mei XP, Liu JT, et al
    Propofol suppressed cell proliferation and enhanced apoptosis of bladder cancer cells by regulating the miR-340/CDK2 signal axis.
    Acta Histochem. 2021;123:151728.
    PubMed    
    Abstract available

  191. SAWAZAKI H, Ito K, Asano T, Kuroda K, et al
    Expressions of P-Glycoprotein, Multidrug Resistance Protein 1 and Annexin A2 as Predictive Factors for Intravesical Recurrence of Bladder Cancer after the Initial Transurethral Resection and Immediate Single Intravesical Instillation of Adriamycin.
    Asian Pac J Cancer Prev. 2021;22:1459-1466.
    PubMed    
    Abstract available

  192. FERRO M, de Cobelli O, Musi G, Lucarelli G, et al
    Three vs. Four Cycles of Neoadjuvant Chemotherapy for Localized Muscle Invasive Bladder Cancer Undergoing Radical Cystectomy: A Retrospective Multi-Institutional Analysis.
    Front Oncol. 2021;11:651745.
    PubMed    
    Abstract available

  193. SOUAID T, Hindy JR, Diab E, Kourie HR, et al
    Are there monogenic hereditary forms of bladder cancer or only genetic susceptibilities?
    Pharmacogenomics. 2021 May 28. doi: 10.2217/pgs-2020-0165.
    PubMed    
    Abstract available

  194. CHEN Y, Wang HH, Chang HH, Huang YH, et al
    Guggulsterone induces apoptosis and inhibits lysosomal-dependent migration in human bladder cancer cells.
    Phytomedicine. 2021;87:153587.
    PubMed    
    Abstract available

  195. GE R, Cai H, Yuan X, Qin F, et al
    MD-UNET: Multi-input dilated U-shape neural network for segmentation of bladder cancer.
    Comput Biol Chem. 2021;93:107510.
    PubMed    
    Abstract available

  196. HAAS M, Burger M, Schnabel MJ
    [Systemic treatment of bladder cancer].
    Urologe A. 2021 May 27. pii: 10.1007/s00120-021-01535.
    PubMed    
    Abstract available

  197. HUANG Y, Wang T
    Pectin Oligosaccharides Enhance alpha2,6-Sialylation Modification that Promotes Apoptosis of Bladder Cancer Cells by Targeting the Hedgehog Pathway.
    Cell Biochem Biophys. 2021 May 26. pii: 10.1007/s12013-021-00996.
    PubMed    
    Abstract available

  198. CAI Z, Chen H, Bai J, Zheng Y, et al
    Copy Number Variations of CEP63, FOSL2 and PAQR6 Serve as Novel Signatures for the Prognosis of Bladder Cancer.
    Front Oncol. 2021;11:674933.
    PubMed    
    Abstract available

  199. TEE JL, Chambers J, Strutton G
    Bladder perivascular epithelioid cell tumour and tuberous sclerosis complex: a rare association.
    BMJ Case Rep. 2021;14.
    PubMed    
    Abstract available

  200. DIANATINASAB M, Wesselius A, de Loeij T, Salehi-Abargouei A, et al
    The association between meat and fish consumption and bladder cancer risk: a pooled analysis of 11 cohort studies.
    Eur J Epidemiol. 2021 May 25. pii: 10.1007/s10654-021-00762.
    PubMed    
    Abstract available

  201. MA Y, Huang Z, Jian Z, Wei X, et al
    The association between hepatitis C virus infection and renal cell cancer, prostate cancer, and bladder cancer: a systematic review and meta-analysis.
    Sci Rep. 2021;11:10833.
    PubMed    
    Abstract available

  202. HUANG Z, Yan Y, Zhu Z, Liu J, et al
    CBX7 suppresses urinary bladder cancer progression via modulating AKR1B10-ERK signaling.
    Cell Death Dis. 2021;12:537.
    PubMed    
    Abstract available

  203. HUGHES S, Kass-Iliyya A
    Isolated penile metastases secondary to invasive bladder cancer.
    BMJ Case Rep. 2021;14.
    PubMed    


  204. JIA W, Luo S, Lai G, Li S, et al
    Homogeneous polyporus polysaccharide inhibits bladder cancer by polarizing macrophages to M1 subtype in tumor microenvironment.
    BMC Complement Med Ther. 2021;21:150.
    PubMed    
    Abstract available

  205. ELBADAWY M, Sato Y, Mori T, Goto Y, et al
    Anti-tumor effect of trametinib in bladder cancer organoid and the underlying mechanism.
    Cancer Biol Ther. 2021 May 26:1-15. doi: 10.1080/15384047.2021.1919004.
    PubMed    
    Abstract available

  206. FRAGKOULIS C, Glykas I, Mari V, Lamprou S, et al
    Incidental prostate cancer in patients who underwent radical cystectomy for high risk non muscle invasive bladder cancer: Is it clinically significant?
    Urologia. 2021 May 25:3915603211019989. doi: 10.1177/03915603211019989.
    PubMed    
    Abstract available

  207. WANG J, Shen C, Zhang J, Zhang Y, et al
    TEAD4 Is an Immune Regulating-Related Prognostic Biomarker for Bladder Cancer and Possesses Generalization Value in Pan-Cancer.
    DNA Cell Biol. 2021 May 24. doi: 10.1089/dna.2021.0164.
    PubMed    
    Abstract available

  208. SHOU J, Zhang Q, Zhang D
    The prognostic effect of metastasis patterns on overall survival in patients with distant metastatic bladder cancer: a SEER population-based analysis.
    World J Urol. 2021 May 24. pii: 10.1007/s00345-021-03721.
    PubMed    
    Abstract available

  209. CARDWELL CR, McDowell RD, Hughes CM, Hicks B, et al
    Exposure to Ranitidine and Risk of Bladder Cancer: A Nested Case-Control Study.
    Am J Gastroenterol. 2021 May 21. pii: 00000434-900000000-98771.
    PubMed    
    Abstract available

  210. HAFEEZ S, Dunlop A, Mitchell A, Nill S, et al
    Comment on Hunt et al., "Feasibility of magnetic resonance guided radiotherapy for the treatment of bladder cancer".
    Clin Transl Radiat Oncol. 2021;29:9-10.
    PubMed    


  211. JIANG M, Ren L, Chen Y, Wang H, et al
    Identification of a Hypoxia-Related Signature for Predicting Prognosis and the Immune Microenvironment in Bladder Cancer.
    Front Mol Biosci. 2021;8:613359.
    PubMed    
    Abstract available

  212. CHEN YS, Xu YP, Liu WH, Li DC, et al
    Long Noncoding RNA KCNMB2-AS1 Promotes SMAD5 by Targeting miR-3194-3p to Induce Bladder Cancer Progression.
    Front Oncol. 2021;11:649778.
    PubMed    
    Abstract available

  213. SU S, Liu L, Sun C, Nie Y, et al
    Preoperative Serum Gamma-Glutamyltransferase as a Prognostic Biomarker in Patients Undergoing Radical Cystectomy for Bladder Cancer.
    Front Oncol. 2021;11:648904.
    PubMed    
    Abstract available

  214. SCHUETTFORT VM, Pradere B, Trinh QD, D'Andrea D, et al
    Impact of preoperative plasma levels of interleukin 6 and interleukin 6 soluble receptor on disease outcomes after radical cystectomy for bladder cancer.
    Cancer Immunol Immunother. 2021 May 23. pii: 10.1007/s00262-021-02953.
    PubMed    
    Abstract available

  215. CRONISE KE, Das S, Hernandez BG, Regan DP, et al
    Characterizing the Molecular and Immune Landscape of Canine Bladder Cancer.
    Vet Comp Oncol. 2021 May 22. doi: 10.1111/vco.12740.
    PubMed    
    Abstract available

  216. YIN YW, Liu KL, Lu BS, Li W, et al
    RBM24 exacerbates bladder cancer progression by forming a Runx1t1/TCF4/miR-625-5p feedback loop.
    Exp Mol Med. 2021 May 21. pii: 10.1038/s12276-021-00623.
    PubMed    
    Abstract available

  217. MONOE Y, Jingushi K, Kawase A, Hirono T, et al
    Pharmacological Inhibition of miR-130 Family Suppresses Bladder Tumor Growth by Targeting Various Oncogenic Pathways via PTPN1.
    Int J Mol Sci. 2021;22.
    PubMed    
    Abstract available

  218. ZHANG Q, Wu J, Chen X, Zhao M, et al
    Upregulation of Versican Associated with Tumor Progression, Metastasis, and Poor Prognosis in Bladder Carcinoma.
    Biomed Res Int. 2021;2021:6949864.
    PubMed    
    Abstract available

  219. BOHLE A
    [Intravesical gene therapy for patients with BCG-refractory NMIBC?]
    Urologe A. 2021;60:372-373.
    PubMed    


  220. LEE JH, Lee KH, Kim JH
    In Silico Inference of Synthetic Cytotoxic Interactions from Paclitaxel Responses.
    Int J Mol Sci. 2021;22.
    PubMed    
    Abstract available



  221. Urologe A. 2021;60:140-141.
    PubMed    


  222. EBRAHIM HM, Asaad AM, El Desoky F, Morsi HM, et al
    Bacillus Calmette-Guerin polysaccharide nucleic acid vs Bacillus Calmette-Guerin vaccine in the treatment of warts: A comparative, double-blind, controlled study.
    Dermatol Ther. 2021;34:e14549.
    PubMed    
    Abstract available

  223. MISTRETTA FA, Musi G, Colla Ruvolo C, Conti A, et al
    Robot-Assisted Radical Cystectomy for Nonmetastatic Urothelial Carcinoma of Urinary Bladder: A Comparison Between Intracorporeal Versus Extracorporeal Orthotopic Ileal Neobladder.
    J Endourol. 2021;35:151-158.
    PubMed    
    Abstract available

  224. YOU C, Du Y, Wang H, Peng L, et al
    Robot-Assisted Radical Cystectomy with Intracorporeal Urinary Diversion: A New Standard of Urinary Diversion.
    J Endourol. 2021;35:473-482.
    PubMed    
    Abstract available

  225. XIAO H, Alisic H, Reiman BT, Deng Z, et al
    IL-39 Reduces Proliferation and Promotes Apoptosis of Bladder Cancer by Altering the Activity of Cyclin E and Fas.
    Anticancer Res. 2021;41:2239-2245.
    PubMed    
    Abstract available

  226. RAVI P, Pond GR, Diamantopoulos LN, Su C, et al
    Optimal Pathologic Response After Neoadjuvant Chemotherapy For Muscle-Invasive Bladder Cancer: Results From A Global, Multi-Center Collaboration.
    BJU Int. 2021 Apr 28. doi: 10.1111/bju.15434.
    PubMed    
    Abstract available

  227. FUKUOKAYA W, Kimura T, Yanagisawa T, Kimura S, et al
    Comparison of the Immunotherapy Response Evaluation Criteria in Solid Tumours (iRECIST) with RECIST for capturing treatment response of patients with metastatic urothelial carcinoma treated with pembrolizumab.
    BJU Int. 2021;127:90-95.
    PubMed    
    Abstract available

  228. SARI MOTLAGH R, Mori K, Miura N, Quhal F, et al
    The recurrence and progression risk after simultaneous endoscopic surgery of urothelial bladder tumor and benign prostatic hyperplasia; a systematic review and meta-analysis.
    BJU Int. 2020 Jun 21. doi: 10.1111/bju.15146.
    PubMed    
    Abstract available

  229. MOE A, Liow E, Redfern A, Swarbrick N, et al
    A phase I open label dose-escalation study to evaluate the tolerability, safety and immunological efficacy of sub-urothelial durvalumab injection in adults with muscle-invasive or high-risk non-muscle-invasive bladder cancer (SUBDUE-1, SUB-urothelial
    BJU Int. 2021 May 6. doi: 10.1111/bju.15365.
    PubMed    
    Abstract available

  230. JAHNSON S, Soderkvist P, Aljabery F, Olsson H, et al
    TERT mutation and the p53 pathway in T1 urinary bladder cancer.
    BJU Int. 2021 May 24. doi: 10.1111/bju.15490.
    PubMed    
    Abstract available

  231. FENG L, Fu D, Gao L, Cheng H, et al
    Circular RNA_0001495 increases Robo1 expression by sponging microRNA-527 to promote the proliferation, migration and invasion of bladder cancer cells.
    Carcinogenesis. 2021 May 22. pii: 6280236. doi: 10.1093.
    PubMed    
    Abstract available

  232. BORCSOK J, Diossy M, Sztupinszki Z, Prosz A, et al
    Detection of Molecular Signatures of Homologous Recombination Deficiency in Bladder Cancer.
    Clin Cancer Res. 2021 May 4. pii: 1078-0432.CCR-20-5037.
    PubMed    
    Abstract available

  233. DRAKE CG
    Myeloid Resistance is Not Futile: Biomarkers of Immunotherapy in Bladder Cancer.
    Clin Cancer Res. 2021 May 27. pii: 1078-0432.CCR-21-1011.
    PubMed    
    Abstract available

  234. HASANALI SL, Morera DS, Racine RR, Hennig M, et al
    HYAL4-V1/Chondroitinase (Chase) Drives Gemcitabine Resistance and Predicts Chemotherapy Failure in Patients with Bladder Cancer.
    Clin Cancer Res. 2021 May 24. pii: 1078-0432.CCR-21-0422.
    PubMed    
    Abstract available

  235. CHAN EO, Pradere B, Teoh JY
    The use of artificial intelligence for the diagnosis of bladder cancer: a review and perspectives.
    Curr Opin Urol. 2021 May 11. pii: 00042307-900000000-98866.
    PubMed    
    Abstract available

  236. ZIMMERMANN K, Mostafaei H, Heidenreich A, Schmelz HU, et al
    Health-related quality of life in bladder cancer patients: bladder cancer-specific instruments and domains. Part 2.
    Curr Opin Urol. 2021 May 10. pii: 00042307-900000000-98868.
    PubMed    
    Abstract available

  237. SCHUETTFORT VM, Pradere B, Comperat E, Abufaraj M, et al
    Novel transurethral resection technologies and training modalities in the management of nonmuscle invasive bladder cancer: a comprehensive review.
    Curr Opin Urol. 2021 May 10. pii: 00042307-900000000-98867.
    PubMed    
    Abstract available

  238. ZIMMERMANN K, Mostafaei H, Heidenreich A, Schmelz HU, et al
    Part I. Health-related quality of life in bladder cancer patients: general and cancer-specific instruments.
    Curr Opin Urol. 2021 May 6. pii: 00042307-900000000-98874.
    PubMed    
    Abstract available


  239. Bladder-preserving strategies for Bacillus Calmette-Guerin unresponsive non-muscle invasive bladder cancer; where are we and what will be expected?: Erratum.
    Curr Opin Urol. 2021;31:436.
    PubMed    


  240. ABUFARAJ M, Al-Ani A, AlQudah A, Shariat SF, et al
    Surgical intervention in patients with urothelial carcinoma of the bladder and lymph node metastasis.
    Curr Opin Urol. 2021;31:220-225.
    PubMed    
    Abstract available

  241. ROUANNE M, Arpaia N, Marabelle A
    CXCL13 shapes tertiary lymphoid structures and promotes response to immunotherapy in bladder cancer.
    Eur J Cancer. 2021 May 7. pii: S0959-8049(21)00222.
    PubMed    


  242. ALFRED WITJES J
    Re: Optimal Cystectomy Outcome: A Composite Measurement Evaluating Quality of Care and Mortality Benefit.
    Eur Urol. 2021;79:316.
    PubMed    


  243. FODE M, Jensen CFS, Ostergren PB
    How Should the Medical Community Respond to the Low Quality of Medical Information on Social Media?
    Eur Urol. 2021;79:60-61.
    PubMed    


  244. BRYAN RT, Catto JWF, Jefferson KP, Patel P, et al
    Reply to Trey Durdin, Alvin Goh, and Eugene Pietzak. Can an Imaging-guided Pathway Replace the Current Paradigm for Muscle-invasive Bladder Cancer? Eur Urol. In press. https://doi.org/10.1016/j.eururo.2021.03.018.
    Eur Urol. 2021 May 7. pii: S0302-2838(21)00313.
    PubMed    


  245. SUNDAR S, Symonds P
    Re: Syed A. Hussain, Nuria Porta, Emma Hall, et al. Outcomes in Patients with Muscle-invasive Bladder Cancer Treated with Neoadjuvant Chemotherapy Followed by (Chemo)radiotherapy in the BC2001 Trial. Eur Urol 2021;79:307-15.
    Eur Urol. 2021 May 20. pii: S0302-2838(21)00345.
    PubMed    


  246. KIM CJ, Terado T, Tambe Y, Mukaisho KI, et al
    Cryptotanshinone, a novel PDK 4 inhibitor, suppresses bladder cancer cell invasiveness via the mTOR/betacatenin/Ncadherin axis.
    Int J Oncol. 2021;59.
    PubMed    
    Abstract available

  247. PIAO XM, Hwang B, Jeong P, Byun YJ, et al
    Collagen type VIalpha1 and 2 repress the proliferation, migration and invasion of bladder cancer cells.
    Int J Oncol. 2021;59.
    PubMed    
    Abstract available

  248. INOKUCHI J, Kuroiwa K, Nishiyama H, Kojima T, et al
    Significance of the timing of ureteral ligation on prognosis during radical nephroureterectomy for upper urinary tract urothelial cancer.
    Int J Urol. 2021;28:208-214.
    PubMed    
    Abstract available

  249. KUROBE M
    Editorial Comment from Dr Kurobe to Telomerase reverse transcriptase promoter mutation in tumorigenesis of bladder cancer: Evolutionary trajectory by algorithmic inference from cross-sectional data.
    Int J Urol. 2021 May 3. doi: 10.1111/iju.14594.
    PubMed    


  250. IQBAL U, Durrani MM, Elsayed AS, Hussein AA, et al
    Functional outcomes after robot-assisted radical cystectomy: A review of literature.
    Int J Urol. 2021;28:493-501.
    PubMed    
    Abstract available

  251. FARAJ KS, Rose KM, Navaratnam AK, Abdul-Muhsin HM, et al
    Effect of intracorporeal urinary diversion on the incidence of benign ureteroenteric stricture after cystectomy.
    Int J Urol. 2021;28:593-597.
    PubMed    
    Abstract available

  252. FAN J, Wu K, Zhang N, Yang T, et al
    Green-light laser en bloc resection versus conventional transurethral resection for initial non-muscle-invasive bladder cancer: A randomized controlled trial.
    Int J Urol. 2021 May 19. doi: 10.1111/iju.14592.
    PubMed    
    Abstract available

  253. MIYATA Y, Matsuo T, Sakai H
    Editorial Comment to Green-light laser en bloc resection versus conventional transurethral resection for initial non-muscle-invasive bladder cancer: A randomized controlled trial.
    Int J Urol. 2021 May 19. doi: 10.1111/iju.14607.
    PubMed    


  254. SLUSARCZYK A, Garbas K, Zapala P, Zapala L, et al
    Oncological outcomes of high-grade T1 non-muscle-invasive bladder cancer treatment in octogenarians.
    Int Urol Nephrol. 2021 Apr 26. pii: 10.1007/s11255-021-02870.
    PubMed    
    Abstract available

  255. CHAKIRYAN NH, Jiang DD, Gillis KA, Green E, et al
    Pathologic Downstaging and Survival Outcomes Associated with Neoadjuvant Chemotherapy for Variant Histology Muscle Invasive Bladder Cancer.
    J Urol. 2021 May 25:101097JU0000000000001855. doi: 10.1097/JU.0000000000001855.
    PubMed    
    Abstract available

  256. MARTINI A, Afferi L, Zamboni S, Schultz JG, et al
    Oncologic Surveillance for Variant Histology Bladder Cancer after Radical Cystectomy.
    J Urol. 2021 May 25:101097JU0000000000001886. doi: 10.1097/JU.0000000000001886.
    PubMed    
    Abstract available

  257. NABAVIZADEH B, Amend GM, Breyer BN
    Workers Died of Dyes: The Discovery of Occupational Bladder Cancers.
    Urology. 2021 May 16. pii: S0090-4295(21)00400.
    PubMed    


  258. ZHANG Z, Yu Y, Zhang P, Ma G, et al
    Identification of NTRK3 as a potential prognostic biomarker associated with tumor mutation burden and immune infiltration in bladder cancer.
    BMC Cancer. 2021;21:458.
    PubMed    
    Abstract available

  259. YONEYAMA T, Hatakeyama S, Sutoh Yoneyama M, Yoshiya T, et al
    Tumor vasculature-targeted (10)B delivery by an Annexin A1-binding peptide boosts effects of boron neutron capture therapy.
    BMC Cancer. 2021;21:72.
    PubMed    
    Abstract available

  260. CHAN LC, Kalyanasundram J, Leong SW, Masarudin MJ, et al
    Persistent Newcastle disease virus infection in bladder cancer cells is associated with putative pro-survival and anti-viral transcriptomic changes.
    BMC Cancer. 2021;21:625.
    PubMed    
    Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Bladder Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design:


;